Bajaj HealthCare Limited (NSE:BAJAJHCARE)
India
· Delayed Price · Currency is INR | Market Cap | 16.30B |
| Revenue (ttm) | 5.22B |
| Net Income (ttm) | -16.07M |
| Shares Out | n/a |
| EPS (ttm) | -0.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 1.00 (0.19%) |
| Ex-Dividend Date | Sep 23, 2024 |
| Volume | 352,133 |
| Average Volume | 289,365 |
| Open | 521.10 |
| Previous Close | 521.10 |
| Day's Range | 504.00 - 536.10 |
| 52-Week Range | 263.30 - 745.00 |
| Beta | 0.46 |
| RSI | 29.52 |
| Earnings Date | May 23, 2025 |
About Bajaj HealthCare
Bajaj HealthCare Limited, a pharmaceutical company, develops, manufactures, markets, and sells active pharmaceutical ingredient, intermediates, and finished dosage forms and nutraceuticals for pharmaceutical, nutraceuticals, and food industries in India and internationally. The company offers active pharmaceutical ingredient in various therapeutic categories, including anti-diabetic, antibiotic, antiviral, antiplatelet, antifungal, iron-chelating agent, anticonvulsant, growth stimulant, non-steroidal anti-inflammatory drugs, antihypertensive, a... [Read more]
Financial Performance
Financial StatementsNews
Bajaj Healthcare shares rise nearly 3% as company acquires GenRx Pharmaceuticals to strengthen manufacturing footprint
Shares of Bajaj Healthcare Ltd climbed nearly 3% to ₹586.15 in Monday’s early trade following the company’s announcement of a strategic acquisition. As of April 8, the stock was trading higher by ₹16....
Bajaj Healthcare shares rise 5% in weak market as Q3 revenue jumps 13% YoY
Shares of Bajaj Healthcare Ltd surged 4.30% to ₹616.40 on Tuesday, outperforming the weak market sentiment following the company’s Q3 FY25 earnings report. The pharmaceutical company posted a net prof...
Corporate Earnings to Watch on February 11: Lupin, Vodafone Idea, Berger Paints, IRCTC, SAIL, and More
Several companies across pharmaceuticals, telecom, infrastructure, real estate, and consumer goods are set to release their quarterly earnings on February 11, 2025. Investors will closely track these ...
Bajaj Healthcare secures DCGI approval to manufacture Pimavanserin in India
Bajaj Healthcare Limited has received approval from the Drug Controller General of India (DCGI) to manufacture both the Active Pharmaceutical Ingredient (API) and Drug Formulation of Pimavanserin, a 3...
Bajaj Healthcare shares surge 12% after securing exclusive rights for Magtein® in India
Bajaj Healthcare’s stock jumped 12% following its announcement of securing exclusive rights for the manufacturing, distribution, and sales of Magnesium L Threonate (Magtein®) in India. The company sig...
Bajaj Healthcare secures exclusive rights for Magtein® in India from Threotech LLC
Bajaj Healthcare Limited has announced that it has received exclusive rights for the manufacturing, distribution, and sales of the finished formulation of Magnesium L Threonate (Magtein®) in India. Th...
Bajaj Healthcare shares surge 2% on new CDMO agreement with UK/EU clients
Bajaj Healthcare Ltd. saw a 2% rise in its stock price after announcing a definitive Contract Development and Manufacturing Organization (CDMO) agreement with UK/EU-based companies. The deal involves ...
Bajaj Healthcare signs CDMO contract for 15 new APIs with UK/EU companies
The new API pipeline includes a mix of off-patent generic APIs and APIs still under patent.
Bajaj Healthcare shares surge 5% to hit 52-week high after company gets TGA nod for Vadodara unit
Bajaj Healthcare Ltd’s shares soared by 5% to reach a 52-week high of ₹456, following approval from the Therapeutic Goods Administration (TGA) of Australia for its Active Pharmaceutical Ingredient (AP...
Bajaj Healthcare shares surge 6% after company signs development and supply agreement with a European entity
Bajaj Healthcare shares jumped more than 6% after the company entered into a development and supply agreement with a European entity. After its development, this API will be initially supplied in smal...
Bajaj Healthcare enters into a development and supply agreement with a European entity
Bajaj Healthcare Limited has recently informed exchanges that the company has signed a development and supply agreement for an Active Pharmaceutical Ingredient (API) with a European entity. Following ...